Merck's Experimental Cholesterol Drug Shows Early Promise, But Diversification Remains Distant Amid Keytruda Overhang

What happened

Merck announced that its experimental cholesterol treatment enlicitide outperformed a triplet of medications in trials, highlighting progress in non-oncology R&D. This development occurs as Merck aggressively diversifies its pipeline through acquisitions like Cidara and cost-cutting to bridge the looming Keytruda loss-of-exclusivity (LOE) post-2028. However, the cholesterol candidate is early-stage and unlikely to contribute materially to near-term earnings, which are pressured by Gardasil China sales weakness and a ~$9.0B IPR&D charge from the Cidara deal expected in 1Q26. The DeepValue report rates MRK as 'WAIT', emphasizing the need for observable proof points such as accelerating Keytruda Qlex uptake and clean regulatory outcomes by April 2026. Thus, while enlicitide's success is a positive pipeline signal, it does not address the immediate operational hurdles that define Merck's current investment thesis.

Implication

The positive enlicitide data adds a potential future revenue stream, reinforcing Merck's strategy to reduce oncology concentration ahead of Keytruda's patent cliff. However, investors should remain cautious as cholesterol drugs face intense competition and lengthy development timelines, with no near-term commercial impact. More critical for stock performance are imminent catalysts like the Apr 7, 2026 PDUFA for Keytruda variants and quarterly disclosures on subcutaneous Keytruda Qlex adoption, which the DeepValue report identifies as key to franchise defense. Additionally, the expected ~$9.0B IPR&D charge from the Cidara acquisition will pressure 1Q26 EPS, underscoring the trade-off between pipeline building and short-term financial optics. Overall, this news does not alter the 'WAIT' rating, as MRK's valuation at $115.37 already discounts pipeline potential but requires concrete evidence of execution on cost savings and Keytruda retention.

Thesis delta

The enlicitide trial results slightly enhance Merck's pipeline credibility but do not shift the core investment thesis, which remains dependent on near-term operational confirmation. Investors should still prioritize monitoring Keytruda Qlex uptake acceleration and restructuring progress toward $3.0B annual savings by end-2027, as these factors are more decisive for bridging the LOE gap.